Gilead accused of illegally paying to delay HIV drug competition
Biopharmaceutical company Gilead is being sued for allegedly scheming to prevent a generic rival from releasing a competing version of its HIV drug Truvada, according to a class action lawsuit filed by investors in the drug manufacturer.
Boehringer Ingelheim loses parasite control patent appeal
The Federal Court of Australia has rejected Boehringer Ingelheim’s animal health unit's attempt to stop the registration of a patent owned by Intervet International on various grounds.
LSPN Connect: Challenges in the US patent landscape
Innovations in life sciences have dramatically advanced the quality of US healthcare, while diagnostic tests and drug therapies that once seemed beyond our grasp have now become standard.
Biogen loses another battle over MS drug patent
In a blow for biotechnology company, Biogen, a US federal judge has ruled that its lone surviving patent on multiple-sclerosis drug Tecfidera should remain invalid because the matter had already been resolved by another court.
EPO revokes Copaxone patent, clears path for Mylan
The European Patent Office has invalidated and revoked a patent related to Teva’s multiple sclerosis drug Copaxone, in a win for Mylan.
Merck & Co to buy $1bn stake in Seattle Genetics
Merck & Co is set to make a $1 billion investment in biotech company Seattle Genetics, as the companies collaborate to develop and sell Seattle Genetics’ cancer therapy, ladiratuzumab vedotin.
Orexo sues Sun Pharma over opioid dependence generic
Swedish pharmaceutical company Orexo has taken India-based Sun Pharmaceutical to court in the US, over its plans to launch a generic version of Orexo’s opioid dependence treatment.
Judge gives initial approval to Actavis $20m antitrust deal
A Massachusetts judge has provided her preliminary approval to a $19.9 million settlement in a class action antitrust suit brought against pharmaceutical company Actavis.
Broad and ERS Genomics both claim victory in latest CRISPR ruling
The Broad Institute and ERS Genomics, a company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, have both claimed victory in the latest round of the CRISPR inventorship battle.
Gilead to buy Immunomedics for $21bn
Gilead Sciences is set to acquire biopharmaceutical company Immunomedics in a $21 billion deal, further strengthening its oncology expertise.
